The turn formation at positions 22 and 23 in the 42-mer amyloid β peptide: The emerging role in the pathogenesis of Alzheimer's disease

Geriatrics and Gerontology International

Volumn 10, Issue SUPPL. 1, 2010, Pages

  Murakami, Kazuma ^a,b   Masuda, Yuichi ^b   Shirasawa, Takuji ^c   Shimizu, Takahiko ^a   Irie, Kazuhiro ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer's disease; Amyloid; Electron spin resonance; Nuclear magnetic resonance; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE; BRAIN PROTEIN; CARBOXYLIC ACID; COPPER; DNA; FREE RADICAL; GAMMA SECRETASE; GLUTATHIONE REDUCTASE; HYDROGEN PEROXIDE; IRON; LIPID; SCAVENGER RECEPTOR; SUPEROXIDE DISMUTASE; ZINC; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AMYLOIDOSIS; ATOMIC FORCE MICROSCOPY; BETA SHEET; BRAIN; BRAIN HEMORRHAGE; CELL STRAIN; COGNITIVE DEFECT; ELECTRON MICROSCOPY; ELECTRON SPIN RESONANCE; ENDOPLASMIC RETICULUM; GENE DELETION; GENE MUTATION; HUMAN; LIPID PEROXIDATION; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OXIDATIVE STRESS; PATHOGENESIS; POSITION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN STRUCTURE; REVIEW; SENILE PLAQUE; SOLID STATE LASER; VASCULAR AMYLOIDOSIS; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PROTEIN CONFORMATION; PROTEIN PROCESSING;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ELECTRON SPIN RESONANCE SPECTROSCOPY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; AMYLOID BETA-PEPTIDES;

EID: 77954688012     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2010.00598.x     Document Type: Review

References (100)

1. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 2007, 8:101-112.
2. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984, 120:885-890.
3. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (β) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986, 83:4913-4917.
4. Goate A, Chartier-Harlin MC, Mullan M. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349:704-706.
5. Iwatsubo T, Mann DM, Odaka A, Suzuki N, Ihara Y. Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in Down syndrome. Ann Neurol 1995, 37:294-299.
6. Vassar R, Bennett BD, Babu-Khan S. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
7. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron 1994, 13:45-53.
8. Davis J, Van Nostrand WE. Enhanced pathologic properties of Dutch-type mutant amyloid β-protein. Proc Natl Acad Sci USA 1996, 93:2996-3000.
9. Jarrett JT, Lansbury PT. Seeding " one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993, 73:1055-1058.
10. Gomez-Isla T, Hollister R, West H. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997, 41:17-24.
11. Bucciantini M, Giannoni E, Chiti F. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002, 416:507-511.
12. Walsh DM, Klyubin I, Fadeeva JV. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
13. Harper JD, Wong SS, Lieber CM, Lansbury PT. Observation of metastable Aβ amyloid protofibrils by atomic force microscopy. Chem Biol 1997, 4:119-125.
14. Klein WL, Krafft GA, Finch CE. Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 2001, 24:219-224.
15. Hoshi M, Sato M, Matsumoto S. Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β. Proc Natl Acad Sci USA 2003, 100:6370-6375.
16. Lesne S, Koh MT, Kotilinek L. A specific amyloid-β protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
17. Bitan G, Teplow DB. Rapid photochemical cross-linking-a new tool for studies of metastable, amyloidogenic protein assemblies. Acc Chem Res 2004, 37:357-364.
18. Kayed R, Head E, Thompson JL. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
19. Shankar GM, Li S, Mehta TH. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008, 14:837-842.
20. Ancolio K, Dumanchin C, Barelli H. Unusual phenotypic alteration of β amyloid precursor protein (βAPP) maturation by a new Val-715 → Met βAPP-770 mutation responsible for probable early-onset Alzheimer's disease. Proc Natl Acad Sci USA 1999, 96:4119-4124.
21. Scheuner D, Eckman C, Jensen M. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996, 2:864-870.
22. Hendriks L, van Duijn CM, Cras P. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene. Nat Genet 1992, 1:218-221.
23. Levy E, Carman MD, Fernandez-Madrid IJ. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990, 248:1124-1126.
24. Tagliavini F, Rossi G, Padovani A. A new βPP mutation related to hereditary cerebral haemorrhage. Alzheimers Rep 1999, 2:S28.
25. Nilsberth C, Westlind-Danielsson A, Eckman CB. The " Arctic" APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nat Neurosci 2001, 4:887-893.
26. Kamino K, Orr HT, Payami H. Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. Am J Hum Genet 1992, 51:998-1014.
27. Grabowski TJ, Cho HS, Vonsattel JP, Rebeck GW, Greenberg SM. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol 2001, 49:697-705.
28. Melchor JP, McVoy L, Van Nostrand WE. Charge alterations of E22 enhance the pathogenic properties of the amyloid β-protein. J Neurochem 2000, 74:2209-2212.
29. Tomiyama T, Nagata T, Shimada H. A new amyloid β variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 2008, 63:377-387.
30. Di Fede G, Catania M, Morbin M. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009, 323:1473-1477.
31. Shin Y, Cho HS, Fukumoto H. Aβ species, including IsoAsp23 Aβ in Iowa-type familial cerebral amyloid angiopathy. Acta Neuropathol 2003, 105:252-258.
32. Shimizu T, Matsuoka Y, Shirasawa T. Biological significance of isoaspartate and its repair system. Biol Pharm Bull 2005, 28:1590-1596.
33. Roher AE, Lowenson JD, Clarke S. Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 1993, 268:3072-3083.
34. Teplow DB. Structural and kinetic features of amyloid β-protein fibrillogenesis. Amyloid 1998, 5:121-142.
35. Serpell LC. Alzheimer's amyloid fibrils: structure and assembly. Biochim Biophys Acta 2000, 1502:16-30.
36. George AR, Howlett DR. Computationally derived structural models of the β-amyloid found in Alzheimer's disease plaques and the interaction with possible aggregation inhibitors. Biopolymers 1999, 50:733-741.
37. Lazo ND, Downing DT. Amyloid fibrils may be assembled from β-helical protofibrils. Biochem 1998, 37:1731-1735.
38. Tjernberg LO, Callaway DJ, Tjernberg A. A molecular model of Alzheimer amyloid β-peptide fibril formation. J Biol Chem 1999, 274:12619-12625.
39. Lansbury PT, Costa PR, Griffiths JM. Structural model for the β-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide. Nat Struct Biol 1995, 2:990-998.
40. Benzinger TL, Gregory DM, Burkoth TS. Propagating structure of Alzheimer's β-amyloid(10-35) is parallel β-sheet with residues in exact register. Proc Natl Acad Sci USA 1998, 95:13407-13412.
41. Burkoth TS, Benzinger TL, Urban V. Structure of the β-amyloid(10-35) fibril. J Am Chem Soc 2000, 122:7883-7889.
42. Tycko R. Molecular structure of amyloid fibrils: insights from solid-state NMR. Q Rev Biophys 2006, 39:1-55.
43. Antzutkin ON, Leapman RD, Balbach JJ, Tycko R. Supramolecular structural constraints on Alzheimer's β-amyloid fibrils from electron microscopy and solid-state nuclear magnetic resonance. Biochem 2002, 41:15436-15450.
44. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci 2003, 26:207-214.
45. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004, 3:205-214.
46. Butterfield DA. Amyloid β-peptide [1-42]-associated free radical-induced oxidative stress and neurodegeneration in Alzheimer's disease brain: mechanisms and consequences. Curr Med Chem 2003, 10:2651-2659.
47. Hensley K, Hall N, Subramaniam R. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 1995, 65:2146-2156.
48. Huang X, Cuajungco MP, Atwood CS. Cu(II) potentiation of alzheimer Aβ neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 1999, 274:37111-37116.
49. Karr JW, Kaupp LJ, Szalai VA. Amyloid-β binds Cu2+ in a mononuclear metal ion binding site. J Am Chem Soc 2004, 126:13534-13538.
50. Karr JW, Akintoye H, Kaupp LJ, Szalai VA. N-Terminal deletions modify the Cu2+ binding site in amyloid-β. Biochem 2005, 44:5478-5487.
51. Curtain CC, Ali F, Volitakis I. Alzheimer's disease amyloid-β binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 2001, 276:20466-20473.
52. Curtain CC, Ali FE, Smith DG, Bush AI, Masters CL, Barnham KJ. Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-β peptide with membrane lipid. J Biol Chem 2003, 278:2977-2982.
53. Tickler AK, Smith DG, Ciccotosto GD. Methylation of the imidazole side chains of the Alzheimer disease amyloid-β peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity. J Biol Chem 2005, 280:13355-13363.
54. Antzutkin ON. Amyloidosis of Alzheimer's Aβ peptides: solid-state nuclear magnetic resonance, electron paramagnetic resonance, transmission electron microscopy, scanning transmission electron microscopy and atomic force microscopy studies. Magn Reson Chem 2004, 42:231-246.
55. Syme CD, Nadal RC, Rigby SE, Viles JH. Copper binding to the amyloid-β (Aβ) peptide associated with Alzheimer's disease: folding, coordination geometry, pH dependence, stoichiometry, and affinity of Aβ-(1-28): insights from a range of complementary spectroscopic techniques. J Biol Chem 2004, 279:18169-18177.
56. Barnham KJ, Haeffner F, Ciccotosto GD. Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease β-amyloid. FASEB J 2004, 18:1427-1429.
57. Giulian D, Haverkamp LJ, Yu JH. Specific domains of β-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J Neurosci 1996, 16:6021-6037.
58. Petkova AT, Ishii Y, Balbach JJ. A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA 2002, 99:16742-16747.
59. Janssen JC, Beck JA, Campbell TA. Early onset familial Alzheimer's disease: mutation frequency in 31 families. Neurology 2003, 60:235-239.
60. Wakutani Y, Watanabe K, Adachi Y. Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004, 75:1039-1042.
61. Varadarajan S, Yatin S, Kanski J, Jahanshahi F, Butterfield DA. Methionine residue 35 is important in amyloid β-peptide-associated free radical oxidative stress. Brain Res Bull 1999, 50:133-141.
62. Naslund J, Schierhorn A, Hellman U. Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA 1994, 91:8378-8382.
63. Kuo YM, Kokjohn TA, Beach TG. Comparative analysis of amyloid-β chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem 2001, 276:12991-12998.
64. Varadarajan S, Kanski J, Aksenova M, Lauderback C, Butterfield DA. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's Aβ(1-42) and Aβ(25-35). J Am Chem Soc 2001, 123:5625-5631.
65. Kanski J, Aksenova M, Schoneich C, Butterfield DA. Substitution of isoleucine-31 by helical-breaking proline abolishes oxidative stress and neurotoxic properties of Alzheimer's amyloid β-peptide. Free Radic Biol Med 2002, 32:1205-1211.
66. Lin H, Zhu YJ, Lal R. Amyloid β protein (1-40) forms calcium-permeable, Zn2+-sensitive channel in reconstituted lipid vesicles. Biochem 1999, 38:11189-11196.
67. Yan SD, Chen X, Fu J. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382:685-691.
68. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD. Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils. Nature 1996, 382:716-719.
69. Paresce DM, Ghosh RN, Maxfield FR. Microglial cells internalize aggregates of the Alzheimer's disease amyloid β-protein via a scavenger receptor. Neuron 1996, 17:553-565.
70. Yan SD, Fu J, Soto C. An intracellular protein that binds amyloid-β peptide and mediates neurotoxicity in Alzheimer's disease. Nature 1997, 389:689-695.
71. Yip CM, McLaurin J. Amyloid-β peptide assembly: a critical step in fibrillogenesis and membrane disruption. Biophys J 2001, 80:1359-1371.
72. Shimizu T, Fukuda H, Murayama S, Izumiyama N, Shirasawa T. Isoaspartate formation at position 23 of amyloid β peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer's disease. J Neurosci Res 2002, 70:451-461.
73. Miravalle L, Tokuda T, Chiarle R. Substitutions at codon 22 of Alzheimer's Aβ peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J Biol Chem 2000, 275:27110-27116.
74. Wang Z, Natte R, Berliner JA, van Duinen SG, Vinters HV. Toxicity of Dutch (E22Q) and Flemish (A21G) mutant amyloid β proteins to human cerebral microvessel and aortic smooth muscle cells. Stroke 2000, 31:534-538.
75. Murakami K, Irie K, Morimoto A. Synthesis, aggregation, neurotoxicity, and secondary structure of various Aβ1-42 mutants of familial Alzheimer's disease at positions 21-23. Biochem Biophys Res Commun 2002, 294:5-10.
76. Murakami K, Irie K, Morimoto A. Neurotoxicity and physicochemical properties of Aβ mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease. J Biol Chem 2003, 278:46179-46187.
77. Tsubuki S, Takaki Y, Saido TC. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Aβ to physiologically relevant proteolytic degradation. Lancet 2003, 361:1957-1958.
78. Bitan G, Vollers SS, Teplow DB. Elucidation of primary structure elements controlling early amyloid β-protein oligomerization. J Biol Chem 2003, 278:34882-34889.
79. Van Nostrand WE, Melchor JP, Cho HS, Greenberg SM, Rebeck GW. Pathogenic effects of D23N Iowa mutant amyloid β-protein. J Biol Chem 2001, 276:32860-32866.
80. Stenh C, Nilsberth C, Hammarback J, Engvall B, Naslund J, Lannfelt L. The Arctic mutation interferes with processing of the amyloid precursor protein. Neuroreport 2002, 13:1857-1860.
81. Murakami K, Uno M, Masuda Y, Shimizu T, Shirasawa T, Irie K. Isomerization and/or racemization at Asp23 of Aβ42 do not increase its aggregative ability, neurotoxicity, and radical productivity in vitro. Biochem Biophys Res Commun 2008, 366:745-751.
82. Chazin WJ, Kordel J, Thulin E, Hofmann T, Drakenberg T, Forsen S. Identification of an isoaspartyl linkage formed upon deamidation of bovine calbindin D9k and structural characterization by 2D 1H NMR. Biochem 1989, 28:8646-8653.
83. Fairman R, Anthony-Cahill SJ, DeGrado WF. The helix-forming propensity of D-alanine in a right-handed α-helix. J Am Chem Soc 1992, 114:5458-5459.
84. Chou PY, Fasman GD. β-Turns in proteins. J Mol Biol 1977, 115:135-175.
85. Morimoto A, Irie K, Murakami K. Aggregation and neurotoxicity of mutant amyloid β (Aβ) peptides with proline replacement: importance of turn formation at positions 22 and 23. Biochem Biophys Res Commun 2002, 295:306-311.
86. Morimoto A, Irie K, Murakami K. Analysis of the secondary structure of β-amyloid (Aβ42) fibrils by systematic proline replacement. J Biol Chem 2004, 279:52781-52788.
87. Williams AD, Portelius E, Kheterpal I. Mapping Aβ amyloid fibril secondary structure using scanning proline mutagenesis. J Mol Biol 2004, 335:833-842.
88. Murakami K, Hara H, Masuda Y, Ohigashi H, Irie K. Distance measurement between Tyr10 and Met35 in amyloid β by site-directed spin-labeling ESR spectroscopy: implications for the stronger neurotoxicity of Aβ42 than Aβ40. Chembiochem 2007, 8:2308-2314.
89. Takegoshi K, Nakamura S, Terao T. 13C-1H dipolar-driven13C-13C recoupling without13C rf irradiation in nuclear magnetic resonance of rotating solids. J Chem Phys 2003, 118:2325-2341.
90. Masuda Y, Irie K, Murakami K. Verification of the turn at positions 22 and 23 of the β-amyloid fibrils with Italian mutation using solid-state NMR. Bioorg Med Chem 2005, 13:6803-6809.
91. Masuda Y, Uemura S, Ohashi R. Identification of physiological and toxic conformations in Aβ42 aggregates. Chembiochem 2009, 10:287-295.
92. Raleigh DP, Levitt MH, Griffin RG. Rotational resonance in solid state NMR. Chem Phys Lett 1988, 146:71-76.
93. Masuda Y, Nakanishi A, Ohashi R. Verification of the intermolecular parallel β-sheet in E22K-Aβ42 aggregates by solid-state NMR using rotational resonance: implications for the supramolecular arrangement of the toxic conformer of Aβ42. Biosci Biotechnol Biochem 2008, 72:2170-2175.
94. Masuda Y, Uemura S, Nakanishi A. Verification of the C-terminal intramolecular β-sheet in Aβ42 aggregates using solid-state NMR: implications for potent neurotoxicity through the formation of radicals. Bioorg Med Chem Lett 2008, 18:3206-3210.
95. Murakami K, Irie K, Ohigashi H. Formation and stabilization model of the 42-mer Aβ radical: implications for the long-lasting oxidative stress in Alzheimer's disease. J Am Chem Soc 2005, 127:15168-15174.
96. Orgogozo JM, Gilman S, Dartigues JF. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003, 61:46-54.
97. Schenk D, Barbour R, Dunn W. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
98. Morgan D, Diamond DM, Gottschall PE. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
99. Holmes C, Boche D, Wilkinson D. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
100. Horikoshi Y, Sakaguchi G, Becker AG. Development of Aβ terminal end-specific antibodies and sensitive ELISA for Aβ variant. Biochem Biophys Res Commun 2004, 319:733-737.